Probiotics in the intensive care unit

Why controversies and confusion abound

Lee E. Morrow, Marin H. Kollef

Research output: Contribution to journalComment/debate

13 Citations (Scopus)

Abstract

Probiotics are living microorganisms that, when administered in adequate amounts, confer health benefits on the host. Because probiotics are not marketed as pharmaceuticals, they are commercially available without rigorous scientific documentation of their efficacy for many health-related claims. Results from existing clinical trials are both confusing and controversial. The evidence base is relatively limited, includes studies with varied designs, assesses multiple probiotic preparations across discrepant disease states, and provides conflicting results. Recent advances in the delineation of probiotics' mechanisms of action offer the opportunity to construct a more logical framework within which future trials are designed.

Original languageEnglish
Article number160
JournalCritical Care
Volume12
Issue number3
DOIs
StatePublished - Jun 24 2008

Fingerprint

Probiotics
Intensive Care Units
Insurance Benefits
Documentation
Clinical Trials
Health
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Probiotics in the intensive care unit : Why controversies and confusion abound. / Morrow, Lee E.; Kollef, Marin H.

In: Critical Care, Vol. 12, No. 3, 160, 24.06.2008.

Research output: Contribution to journalComment/debate

@article{b5445ed5312b4391a196f73e0678aa26,
title = "Probiotics in the intensive care unit: Why controversies and confusion abound",
abstract = "Probiotics are living microorganisms that, when administered in adequate amounts, confer health benefits on the host. Because probiotics are not marketed as pharmaceuticals, they are commercially available without rigorous scientific documentation of their efficacy for many health-related claims. Results from existing clinical trials are both confusing and controversial. The evidence base is relatively limited, includes studies with varied designs, assesses multiple probiotic preparations across discrepant disease states, and provides conflicting results. Recent advances in the delineation of probiotics' mechanisms of action offer the opportunity to construct a more logical framework within which future trials are designed.",
author = "Morrow, {Lee E.} and Kollef, {Marin H.}",
year = "2008",
month = "6",
day = "24",
doi = "10.1186/cc6927",
language = "English",
volume = "12",
journal = "Critical Care",
issn = "1466-609X",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Probiotics in the intensive care unit

T2 - Why controversies and confusion abound

AU - Morrow, Lee E.

AU - Kollef, Marin H.

PY - 2008/6/24

Y1 - 2008/6/24

N2 - Probiotics are living microorganisms that, when administered in adequate amounts, confer health benefits on the host. Because probiotics are not marketed as pharmaceuticals, they are commercially available without rigorous scientific documentation of their efficacy for many health-related claims. Results from existing clinical trials are both confusing and controversial. The evidence base is relatively limited, includes studies with varied designs, assesses multiple probiotic preparations across discrepant disease states, and provides conflicting results. Recent advances in the delineation of probiotics' mechanisms of action offer the opportunity to construct a more logical framework within which future trials are designed.

AB - Probiotics are living microorganisms that, when administered in adequate amounts, confer health benefits on the host. Because probiotics are not marketed as pharmaceuticals, they are commercially available without rigorous scientific documentation of their efficacy for many health-related claims. Results from existing clinical trials are both confusing and controversial. The evidence base is relatively limited, includes studies with varied designs, assesses multiple probiotic preparations across discrepant disease states, and provides conflicting results. Recent advances in the delineation of probiotics' mechanisms of action offer the opportunity to construct a more logical framework within which future trials are designed.

UR - http://www.scopus.com/inward/record.url?scp=52449117483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449117483&partnerID=8YFLogxK

U2 - 10.1186/cc6927

DO - 10.1186/cc6927

M3 - Comment/debate

VL - 12

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 3

M1 - 160

ER -